181 related articles for article (PubMed ID: 33718513)
21. Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy.
Vragniau C; Hübner JM; Beidler P; Gil S; Saydaminova K; Lu ZZ; Yumul R; Wang H; Richter M; Sova P; Drescher C; Fender P; Lieber A
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077642
[TBL] [Abstract][Full Text] [Related]
22. The combination of NK and CD8+T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells.
Ye JF; Qi WX; Liu MY; Li Y
Cell Immunol; 2017 Aug; 318():35-41. PubMed ID: 28651743
[TBL] [Abstract][Full Text] [Related]
23. Unique conditionally replication competent bipartite adenoviruses-cancer terminator viruses (CTV): efficacious reagents for cancer gene therapy.
Sarkar D; Su ZZ; Fisher PB
Cell Cycle; 2006 Jul; 5(14):1531-6. PubMed ID: 16861924
[TBL] [Abstract][Full Text] [Related]
24. Association of oncolytic adenoviruses with chemotherapies: an overview and future directions.
Bressy C; Benihoud K
Biochem Pharmacol; 2014 Jul; 90(2):97-106. PubMed ID: 24832861
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic adenoviruses expressing interleukin: a novel antitumour approach.
Pei DS; Zheng JN
Expert Opin Biol Ther; 2010 Jun; 10(6):917-26. PubMed ID: 20402550
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic Adenoviruses in Cancer Treatment.
Alemany R
Biomedicines; 2014 Feb; 2(1):36-49. PubMed ID: 28548059
[TBL] [Abstract][Full Text] [Related]
27. A novel oncolytic adenovirus based on simian adenovirus serotype 24.
Cheng T; Song Y; Zhang Y; Zhang C; Yin J; Chi Y; Zhou D
Oncotarget; 2017 Apr; 8(16):26871-26885. PubMed ID: 28460470
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21/IL15 armed oncolytic adenovirus in TERT-positive tumor cells.
Ye JF; Lin YQ; Yu XH; Liu MY; Li Y
Int Immunopharmacol; 2016 Sep; 38():460-7. PubMed ID: 27380620
[TBL] [Abstract][Full Text] [Related]
29. Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity.
Yan Y; Li S; Jia T; Du X; Xu Y; Zhao Y; Li L; Liang K; Liang W; Sun H; Li R
Tumour Biol; 2015 Jun; 36(6):4535-43. PubMed ID: 25627006
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic adenoviruses as antiglioma agents.
Jiang H; McCormick F; Lang FF; Gomez-Manzano C; Fueyo J
Expert Rev Anticancer Ther; 2006 May; 6(5):697-708. PubMed ID: 16759161
[TBL] [Abstract][Full Text] [Related]
31. A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor.
Carette JE; Graat HC; Schagen FH; Mastenbroek DC; Rots MG; Haisma HJ; Groothuis GM; Schaap GR; Bras J; Kaspers GJ; Wuisman PI; Gerritsen WR; van Beusechem VW
Virology; 2007 Apr; 361(1):56-67. PubMed ID: 17184803
[TBL] [Abstract][Full Text] [Related]
32. Replication-selective oncolytic viruses in the treatment of cancer.
Everts B; van der Poel HG
Cancer Gene Ther; 2005 Feb; 12(2):141-61. PubMed ID: 15472714
[TBL] [Abstract][Full Text] [Related]
33. Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer.
Ranki T; Särkioja M; Hakkarainen T; von Smitten K; Kanerva A; Hemminki A
Int J Cancer; 2007 Jul; 121(1):165-74. PubMed ID: 17315187
[TBL] [Abstract][Full Text] [Related]
34. Modulation of viability and maturation of human monocyte-derived dendritic cells by oncolytic adenoviruses.
Schierer S; Hesse A; Müller I; Kämpgen E; Curiel DT; Schuler G; Steinkasserer A; Nettelbeck DM
Int J Cancer; 2008 Jan; 122(1):219-29. PubMed ID: 17764070
[TBL] [Abstract][Full Text] [Related]
35. Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin.
Yoon AR; Kim JH; Lee YS; Kim H; Yoo JY; Sohn JH; Park BW; Yun CO
Hum Gene Ther; 2006 Apr; 17(4):379-90. PubMed ID: 16610926
[TBL] [Abstract][Full Text] [Related]
36. The constitutive expression of the immunomodulatory gp19k protein in E1-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector.
Lee MG; Abina MA; Haddada H; Perricaudet M
Gene Ther; 1995 Jun; 2(4):256-62. PubMed ID: 7552985
[TBL] [Abstract][Full Text] [Related]
37. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses.
Suzuki K; Alemany R; Yamamoto M; Curiel DT
Clin Cancer Res; 2002 Nov; 8(11):3348-59. PubMed ID: 12429621
[TBL] [Abstract][Full Text] [Related]
38. Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region.
Danielsson A; Dzojic H; Nilsson B; Essand M
Cancer Gene Ther; 2008 Apr; 15(4):203-13. PubMed ID: 18188185
[TBL] [Abstract][Full Text] [Related]
39. Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System.
Cerullo V; Capasso C; Vaha-Koskela M; Hemminki O; Hemminki A
Curr Cancer Drug Targets; 2018; 18(2):124-138. PubMed ID: 28464762
[TBL] [Abstract][Full Text] [Related]
40. A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.
Zhang L; Hedjran F; Larson C; Perez GL; Reid T
Cancer Gene Ther; 2015 Jan; 22(1):17-22. PubMed ID: 25525035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
